AntibodySystem는 Primary Antibody Biosimilar - Research Grade 

제품을 전문적으로 생산하는 20년의 경험이 있는 High Quality 제조사입니다. 

제품 설명 

Anti-Guselkumab ELISA Kit

제품 번호

KAJ63102

제품 특징

Catalog No.

KAJ63102

Description

PRINCIPLE OF THE ASSAY This assay employs the quantitative sandwich enzyme immunoassay technique. Guselkumab has been pre-coated onto a microplate. Samples or standards are pipetted into microwells and Anti-Guselkumab will be captured by immobilized Guselkumab. After washing away any unbound substances, a biotin-labeled Guselkumab is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Anti-Guselkumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

Applications

Used for the quantitative determination of Anti-Guselkumab concentration in serum and plasma.

Detection method

Colorimetric

Sample type

Plasma, Serum

Assay type

Quantitative

Range

3.13 - 200 ng/mL

Sensitivity

0.53 ng/mL

Precision

Intra-Assay Precision (Precision within an assay): <10%

Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision.

Inter-Assay Precision (Precision between assays): <15%

Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

Recovery

80-120%

Shipping

2-8 ℃

Stability and Storage

When the kit was stored at the recommended temperature for 6 months, the signal intensity decreased by less than 20%.n.

Alternative Names

CNTO-1959, CAS: 1350289-85-8

Data Image

• 

  Experiment Example
  CALCULATION OF RESULTS
  Average the duplicate readings for each standard and sample. Construct a standard curve by plotting the mean absorbance for each standard on the Y-axis against the concentration on the X-axis and draw a best fit curve through the points on the graph. The data may be linearized by plotting the log of the Anti-Guselkumab concentrations versus the log of the O.D. and the best fit line can be determined by regression analysis. This procedure will produce an adequate but less precise fit of the data. If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

References

Safety of guselkumab and ustekinumab treatment in patients with moderate-to-severe plaque psoriasis combined with latent tuberculosis or inactive hepatitis B virus infection: A retrospective multicenter observational study., PMID:40482822

Understanding Psoriasis Patient Preferences for Biologic Dosing Frequencies: Insights From a Patient Survey., PMID:40476147

Positioning Guselkumab in The Treatment Algorithm of Patients with Crohn's Disease., PMID:40470513

Comparative Efficacy of Different Targeted Therapies in Patients With Moderate-to-Severe Ulcerative Colitis: Systematic Review/Network Meta-Analysis and Mechanistic Overview., PMID:40468857

Guselkumab Is Effective for the Management of Scalp Psoriasis in Both Biologic-Naïve and Biologic-Experienced Patients: Results From a Real-World, Retrospective Study., PMID:40468568

Interleukin-23 Inhibitors for Inflammatory Bowel Disease: Pivotal Trials and Practical Considerations., PMID:40465057

Commentary: Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40463376

Guselkumab (Tremfya) - an IL-23 antagonist for Crohn's disease., PMID:40459404

The effect of IL-17 and IL-23 ınhibitors on hematological ınflammatory parameters in patients with psoriasis vulgaris., PMID:40455345

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks., PMID:40450642

Systematic review of comparative studies on emerging psoriasis treatments: comparing biologics with biologics, small molecule inhibitors with small molecule inhibitors, and biologics with small molecule inhibitors., PMID:40439875

Drug survival of IL-23 and IL-17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study., PMID:40439435

Comparative Efficacy of Ustekinumab and Guselkumab in Improving Itch in Severe Psoriasis Patients., PMID:40432363

Emerging Therapies for Palmoplantar Pustulosis with a Focus on IL-23 Inhibitors., PMID:40429269

Network Meta-Analysis: Efficacy of Biological Therapies and Small Molecules as Maintenance Therapy in Ulcerative Colitis., PMID:40407729

Real-World Utilization of Biologic and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs in Psoriatic Arthritis and Axial Spondyloarthritis: Insights from Sweden and Germany., PMID:40402376

Evaluating changes in baseline characteristics and drug utilisation pattern in patients with moderate-to-severe psoriasis: findings from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Cohort., PMID:40402160

Early-Stage Limited Cutaneous Systemic Sclerosis Successfully Treated With Guselkumab: Possibility of Early Intervention in the Pathogenesis., PMID:40401802

Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe., PMID:40396610

With guselkumab, does the dual mechanisms to inhibit IL-23, help in ulcerative colitis?, PMID:40394835

Risk of adverse events of psoriasis treatment with biologic agents and new small molecules-BIOBADADERM Registry., PMID:40387427

A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment., PMID:40383754

Guselkumab in Psoriatic Arthritis: Therapeutic Impact on Axial and Peripheral Involvement-Monocentric Real-World Evidence., PMID:40364181

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease., PMID:40357993

Biologics for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Network Meta-analysis., PMID:40329054

One-Year Efficacy of Guselkumab Versus Advanced Therapies for the Treatment of Moderately to Severely Active Crohn's Disease: A Network Meta-Analysis., PMID:40327280

Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease., PMID:40324965

Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study., PMID:40319105

Novel Small-Molecule Treatment and Emerging Biological Therapy for Psoriasis., PMID:40299379

EBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis., PMID:40297411

Effectiveness and Safety of Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis in Real-World Practice in Korea: A Prospective, Multicenter, Observational, Postmarketing Surveillance Study., PMID:40293170

Efficacy and Safety of IL-17 and IL-23 Inhibitors in Elderly Patients With Plaque Psoriasis: A Real-World Study., PMID:40285439

New Interleukin-23 Antagonists' Use in Crohn's Disease., PMID:40283885

The role of interleukin inhibitors in the treatment of hidradenitis suppurativa; a systematic review of clinical trials., PMID:40268126

Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort., PMID:40264783

Diffusion dimensionality modeling of subcutaneous/intramuscular absorption of antibodies and long-acting injectables., PMID:40263185

Guselkumab: a safe treatment option for patients with comorbid psoriasis and multiple sclerosis., PMID:40248968

A Long-Term Real-Life Safety Study of Guselkumab in Psoriasis Patients with Infectious Comorbidities, Malignancies or Heart Disease: The EARLY Study., PMID:40238960

Predictive Factors for Super Responder Status and Long-Term Effectiveness of Guselkumab in Psoriasis: A Multicenter Retrospective Study., PMID:40238056

Effects of Guselkumab on the FIB-4 Index in Psoriasis Patients (EGIPT): A Three-Year Study., PMID:40237394

Unveiling the effectiveness and safety spectrum of biologic therapies in psoriasis: a three-year real-world analysis., PMID:40227059

Roflumilast Cream 0.3% for a Patient With Genital Psoriasis Refractory to Other Topical and Systemic Treatments: A Case Report., PMID:40212438

Treatment of Plaque Psoriasis with Guselkumab Reduces Systemic Inflammatory Burden as Measured by Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Monocyte/Lymphocyte Ratio: A post hoc Analysis of Three Randomised Clinical Trials., PMID:40209685

Exploring the Impact of Guselkumab and Risankizumab on Psoriasis in HIV-Positive Patients: Insights From Four Italian Centers., PMID:40176606

Successful Guselkumab Treatment in a Patient with Comorbid Psoriasis and Amyotrophic Lateral Sclerosis: A Case Study and Literature Review., PMID:40166719

A Practical Guide to the Use of Guselkumab for Moderate-Severe Ulcerative Colitis., PMID:40162667

Comparative efficacy of pharmacologic interventions in ulcerative colitis: a network meta analysis., PMID:40156676

Real-world safety and effectiveness of guselkumab in patients with psoriasis: A post-marketing surveillance study through up to week 52 in Japan., PMID:40156259

Guselkumab binding to CD64+ IL-23-producing myeloid cells enhances potency for neutralizing IL-23 signaling., PMID:40145093

Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI Study., PMID:40113101

AntibodySystem의 모든 제품들을 만나 보세요!  

Products

Recombinant Protein

Antibody

Assay Kit

Research Biosimilar

Enzyme

Trending Product

Super-Affinity Antibody

Cell Lysates

Antibodysystem - Official Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"